Loading asset research
enGene Therapeutics Inc. Common Stock
ENGNNasdaq · USD · StocksQuote as of · Exchange session not verified$1.80
+1.98%
Today
ENGN
Loading 1D prices…
Market cap
$120.6M
Volume
651K
52w high
$12.2552w low
$1.40Company profile
enGene Therapeutics Inc. Common Stock
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Sector
Health Care
Industry
Biological Products, (No Diagnostic Substances)
Exchange
Nasdaq
Display currency
USD
Location
Montreal, QC, United States
Employees
81
Fiscal year end
1031
CIK
1980845
Session & valuation
Open$1.80
Previous close$1.77
Day high$1.83
Day low$1.79
30-day avg. volume696.1K
Outstanding shares67M
Diluted EPS-$1.34
Latest annual period
P/E (trailing)-1.35
P/E (forward)-1.25
Price / book0.56
Beta-0.27
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2836
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| BDTXBlack Diamond Therapeutics Inc. Common Stock | $113.5M | $70M | +31952.86% | $0.39 | +1.02% | Buy |
| CRBUCaribou Biosciences Inc. Common Stock | $136.2M | $11.2M | -1327.40% | -$1.59 | -6.57% | Buy |
| LENZLENZ Therapeutics Inc. Common Stock | $142M | $19.1M | -430.25% | -$2.85 | -4.13% | Buy |
| TNYATenaya Therapeutics Inc. Common Stock | $143.5M | $0.00 | — | -$0.59 | -1.29% | Buy |
| ATRAAtara Biotherapeutics Inc. Common Stock | $94.2M | $120.8M | +27.07% | $2.57 | -5.16% | Buy |